Zai Lab Limited Stock Price, News & Analysis

On September 28, 2020, Zai Lab announced its secondary listing on the Hong Kong Stock Exchange (stock code: 9688), successfully closing an offering of 10,564,050 new ordinary shares at HK$562.00 per share, equating to approximately US$72.52 per American depositary share. The gross proceeds from this offering are around HK$5.94 billion before costs. The international underwriters have an over-allotment option for an additional 1,584,600 shares. Zai Lab aims to enhance its presence in the rapidly growing Chinese pharmaceutical market.

Zai Lab Limited (NASDAQ: ZLAB) has successfully completed its secondary listing on the Hong Kong Stock Exchange under stock code '9688'. The listing involved the offering of 10,564,050 new ordinary shares at HK$562.00 per share, translating to approximately US$72.52 per American depositary share. The offering raised approximately HK$5.94 billion in gross proceeds. J.P. Morgan, Goldman Sachs, and Citigroup acted as joint sponsors and bookrunners for the listing. This strategic move aims to enhance Zai Lab’s presence in the fast-growing Asian market.

Zai Lab (SEHK:9688, NASDAQ:ZLAB), a biopharmaceutical company, has officially listed on the Main Board of The Stock Exchange of Hong Kong Limited as of September 27, 2020. The stock opened at HK$613.5, reflecting a 9.16% increase and a market capitalization of HK$52.724 billion. Founded in 2014 with Qiming Venture Partners as its earliest investor, Zai Lab focuses on innovative treatments for cancer, infectious, and autoimmune diseases. The company has a robust pipeline of 16 products, including two already commercialized in Greater China.

Zai Lab Limited (NASDAQ: ZLAB) announced the pricing of its Hong Kong secondary listing of 10,564,050 new ordinary shares at HK$562.00, approximately US$72.52 per ADS. The gross proceeds from this listing are estimated at HK$5.94 billion, with trading beginning on September 28, 2020, subject to regulatory approval. The company plans to utilize the funds for R&D and commercialization of core products, ongoing clinical trials, and expanding its internal pipeline. Notably, Zai Lab's ADSs will continue to be traded on NASDAQ.

Zai Lab Limited (NASDAQ: ZLAB) announced positive results from the NORA study, a Phase 3 trial showcasing niraparib as an effective maintenance therapy for patients with recurrent ovarian cancer. The treatment resulted in a 68% reduction in disease progression or death compared to placebo, with median progression-free survival of 18.3 months versus 5.4 months. An individualized dosing regimen reduced the incidence of hematological adverse events. The study's findings are critical for improving treatment standards in China.

Zai Lab Limited (NASDAQ: ZLAB) announced positive results from the Phase 3 NORA study presented at ESMO 2020, demonstrating that niraparib maintenance treatment led to a 68% reduction in the risk of disease progression or death compared to placebo. The median progression-free survival (PFS) for niraparib was significantly longer at 18.3 months, versus 5.4 months for placebo. An individualized dosing regimen reduced adverse events significantly. The study evaluated 265 patients, marking a key step in addressing treatment options for recurrent ovarian cancer in China.

Zai Lab has announced a Hong Kong public offering of 10,564,050 new ordinary shares, with 771,700 shares available in the public offering and 9,792,350 shares for international investors. The maximum offer price is set at HK$648.00 per share. The shares will be listed on the Hong Kong Stock Exchange under stock code 9688 and will be fully fungible with American depositary shares listed on Nasdaq. Proceeds will support R&D, clinical trials, and general corporate purposes. The application process will be entirely electronic, in line with the company's commitment to sustainability.

Zai Lab Limited (NASDAQ: ZLAB) announced that the China National Medical Products Administration (NMPA) has approved ZEJULA® (niraparib) for maintenance treatment in adults with advanced ovarian cancer following platinum-based chemotherapy. This approval marks ZEJULA as the first PARP inhibitor approved globally for all-comer patients in this context. The company emphasized ZEJULA’s potential to change treatment standards in China, highlighting its efficacy and safety. Zai Lab is actively pursuing several studies related to ZEJULA, which may further enhance its market position in oncology therapeutics.

Zai Lab Limited (NASDAQ: ZLAB) announced that CEO Dr. Samantha Du will present at two upcoming virtual conferences. The presentations are scheduled for September 10, 2020, at Citi’s 15th Annual Biopharma Virtual Conference, and September 29, 2020, at JP Morgan’s Women’s Leadership Conference. These conferences are significant as they provide Zai Lab with opportunities to showcase its innovative biopharmaceutical developments, particularly in cancer, infectious, and autoimmune diseases. Archived replays of the presentations will be accessible on Zai Lab’s investor relations website.